Keywords
risk factors
pathogenesis
treatment
How to Cite
Abstract
Introduction: LADA, or Latent Autoimmune Diabetes of Adults, is a condition characterized by disorders of insulin action and secretion, due to the presence of pancreatic autoantibodies, such as those against GADA. Objective: to evaluate the pathogenesis, risk factors and management of latent autoimmune diabetes in adults. Methodology: This is a bibliographic review that included original articles and systematic reviews in English and Portuguese, which addressed the risk factors, pathogenic components and treatment of LADA, published between 2016 and 2024, selected from the databases PubMed, Scopus and SciELO. After careful selection, 18 articles were chosen to compose this bibliographic review. Result and discussions: The destruction of pancreatic cells is slower than in DM1. Genetic and lifestyle factors, such as excess weight and diet, influence its development. Treatment involves lifestyle changes and insulin therapy, aimed at preserving beta cells and modulating the immune response. Considerations: LADA is a complex condition with genetic and environmental influence, and the various factors that influence the onset of the condition are well known. An integrated and multidisciplinary approach is essential to improve patients quality of life.
References
Andersen MK. New insights into the genetics of latent autoimmune diabetes in adults.Curr Diabetes Rep. 2020;9:43. doi: 10.1007/s11892-020-01330-y
Awata T, Shimada A, Maruyama T, Oikawa Y, Yasukawa N, Kurihara S, et al.. Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the non-insulin-dependent stage: a randomized controlled open-label pilot trial (SPAN-s). Diabetes Ther. 2017;8(5):1123–34. doi: 10.1007/s13300017-0299-7
Buzzetti R, Tuomi T, Mauricio D, Pietropaolo M, Zhou Z, Pozzilli P, et al.. Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes. 2020;69(10):2037–47. doi: 10.2337/dbi20-0017
Carlsson S. Environmental (Lifestyle) Risk Factors for LADA. Curr Diabetes Rev. 2019;3:178–87. doi: 10.2174/1573399814666180716150253
Carlsson S. Lifestyle or Environmental Influences and Their Interaction With Genetic Susceptibility on the Risk of LADA. Front Endocrinol (Lausanne). 2022 Jun 29;13:917850. doi: 10.3389/fendo.2022.917850.
Consórcio RISE. Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care. 2018;41(8):1717–25. doi: 10.2337/dc18-0787.
Cousminer DL, Ahlqvist E, Mishra R, Andersen MK, Chesi A, Hawa MI, et al.. The first genome-wide association study of latent autoimmune diabetes in adults reveals novel insights linking immune and metabolic diabetes. Diabetes Care. 2018;41:2396–403. doi: 10.2337/dc18-1032
Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al.. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S17–s38. doi: 10.2337/dc22-S002
Hjort R, Ahlqvist E, Carlsson PO, Grill V, Groop L, Martinell M, et al.. Overweight, obesity, and risk of LADA: results from a Swedish case-control and Norwegian HUNT Study. Diabetologia. 2018;6:1333–43. doi: 10.1007/s00125-018-4596-0
Liu L, Li X, Xiang Y, Huang G, Lin J, Yang L, et al.. Latent autoimmune diabetes in adults with low-titer GAD antibodies: disease progression similar to type 2 diabetes: a nationwide, multicenter prospective study (LADA China Study 3). Diabetes Care. 2015;38(1):16–21. doi: 10.2337/dc14-1770.
Löfvenborg JE, Carlsson S, Andersson T, Hampe CS, Koulman A, Chirlaque Lopez MD, et al.. Interaction between GAD65 antibodies and dietary fish or polyunsaturated n-3 phospholipid plasma fatty acids in incident adult-onset diabetes: the EPIC-InterAct Study. Diabetes Care. 2021;2:416–24. doi: 10.2337/dc20-1463.
Pan N, Yang S, Niu X. Latent Autoimmune Diabetes in Adults and Metabolic SyndromeA Mini Review. Front Endocrinol (Lausanne). 2022 Jun 28;13:913373. doi: 10.3389/fendo.2022.913373.
Pieralice S, Pozzilli P. Latent Autoimmune Diabetes in Adults: A Review on Clinical Implications and Treatment. Diabetes Metab J. 2018;42(6):451–64. doi: 10.4093/dmj.2018.0190
Rasouli B, Ahlqvist E, Alfredsson L, Andersson T, Carlsson PO, Groop L, et al.. Coffee consumption, genetic susceptibility, and risk of latent autoimmune diabetes in adults: a population-based case-control study. Diabetes Metab. 2018;4:354–60. doi: 10.1016/j.diabet.2018.05.002
Rolandsson O, Hampe CS, Sharp SJ, Ardanaz E, Boeing H, Fagherazzi G, et al.. Autoimmunity plays a role in the onset of diabetes after 40 years of age. Diabetologia. 2020;2:266–77. doi: 10.1007/s00125-019-05016-3
Xiang Y, Liu B, Yun C, Zhou P, Li X, Luo S, et al.. Frequency, clinical characteristics,inflammatory cytokines, and genetic backgrounds of latent autoimmune diabetes in youth-onset type 2 diabetes: results from a cross-sectional, multicenter, clinic-based, national (LADA China) study. Diabetes Obes Metab. 2021;23(6):1282–91.
Yin W, Luo S, Xiao Z, Zhang Z, Liu B, Zhou Z. Latent autoimmune diabetes in adults: a focus on β-cell protection and therapy. Front Endocrinol (Lausanne). 2022 Aug 5;13:959011. doi: 10.3389/fendo.2022.959011.
Zhou Z, Wang X, Yang L, Cheng Y. Altered T cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase-4 inhibitor: a 1year open-label randomized clinical trial. Acta Diabetol. 2019;10(2):375–82. doi: 10.1111/jdi.12873
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Paulo Vytor Cardoso Nobre, Flávia Maria Silva Cavalcante , Nayara Fernanda Amorim Madeiros Ribeiro, Fernanda Maria Silva Cavalcanti, Alícia Caroline da Silva Batista, Ana Klívia Vasconcelos Lacerda, Victor Raposo Lima Dias, Isadora Fonseca Santa Roza, Luma waleska lobo Lou Ferreira, Leopoldo Baracho Macena, José César De Oliveira Cerqueira